In Segment C, participants will get ABBV-744 and oral navitoclax. In Section D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products within 3 days ahead of the https://abbv-744preclinicalstudie57801.blog-eye.com/32111753/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc